专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US4851446A Immunosuppressing method 失效
标题翻译：免疫抑制法
公开(公告)号：US4851446A
公开(公告)日：1989-07-25
申请号：US022409
申请日：1987-03-06
申请人： Hamao Umezawa, deceased , Tomio Takeuchi , Masaaki Ishizuka , Fuminori Abe , Akio Fujii , Teruya Nakamura
发明人： Hamao Umezawa, deceased , Tomio Takeuchi , Masaaki Ishizuka , Fuminori Abe , Akio Fujii , Teruya Nakamura
IPC分类号： A61K31/16 , A61K31/165 , C07C279/18
CPC分类号： A61K31/165 , A61K31/16 , C07C279/18 , Y10S514/885
摘要： The present invention relates to an immunosuppressing method which comprises administering a spergualin-related compound represented by the following formula ##STR1## (wherein R.sub.1 is --(CH.sub.2).sub.4 --, --(CH.sub.2).sub.6 --, ##STR2## R.sub.2 is --(CH.sub.2).sub.2 -- or --CH.dbd.CH--; and R.sub.3 is ##STR3## or pharmacologically acceptable salts thereof in an effective amount to a warm-blood animal.
摘要翻译：本发明涉及一种免疫抑制方法，其包括给予由下式表示的精神药蛋白相关化合物+ TR NH（CH 2）3 NH（其中R 1为 - （CH 2）4 - ， - （CH 2）对于温血动物，R 2是有效量的 - （CH 2）2 - 或-CH = CH-;且R 3是或其药学上可接受的盐。

2. 发明授权

US4778824A Method for suppressing a transplantation immunity and treating an allergic disease and an autoimmune disease 失效
标题翻译：抑制移植免疫和治疗过敏性疾病和自身免疫性疾病的方法
公开(公告)号：US4778824A
公开(公告)日：1988-10-18
申请号：US65613
申请日：1987-06-30
申请人： Hamao Umezawa , Tomio Takeuchi , Masaaki Ishizuka , Fuminori Abe , Akio Fujii , Teruya Nakamura
发明人： Hamao Umezawa , Tomio Takeuchi , Masaaki Ishizuka , Fuminori Abe , Akio Fujii , Teruya Nakamura
IPC分类号： A61K31/16 , A61P37/06 , A61P37/08
CPC分类号： A61K31/16 , Y10S514/885
摘要： This invention relates to method for suppressing a transplantation immunity and treating an allergic disease and an autoimmune disease in a mammal which comprises administering spergualin or a pharmaceutically acceptable salt thereof in effective amount to the said mammal.
摘要翻译：本发明涉及抑制哺乳动物的移植免疫和治疗过敏性疾病和自身免疫性疾病的方法，其包括以有效量向所述哺乳动物施用精神分裂剂或其药学上可接受的盐。

3. 发明申请

US20140249217A1 ENHANCER OF SURVIVAL OF TRANSPLANTED ORGAN 有权
标题翻译：运输机构存货增值
公开(公告)号：US20140249217A1
公开(公告)日：2014-09-04
申请号：US14350488
申请日：2012-09-12
申请人： Ko Rii , Kiwamu Takahashi , Naomi Haga , Fuminori Abe , Tohru Tanaka , Motowo Nakajima , Hidenori Ito
发明人： Ko Rii , Kiwamu Takahashi , Naomi Haga , Fuminori Abe , Tohru Tanaka , Motowo Nakajima , Hidenori Ito
IPC分类号： A61K31/197 , A61K31/295
CPC分类号： A61K31/197 , A01N1/0226 , A61K31/22 , A61K31/295 , A61K33/26 , A61K35/17 , A61K45/06 , A61K2035/122 , A61K2035/124 , A61K2300/00
摘要： The present invention provides an agent for promoting graft survival which can suppress rejection without use of existing immunosuppressants, an organ preservation solution capable of maintaining the freshness of an organ excised from a donor, and the like. An agent for promoting graft survival or an organ preservation solution is prepared, which comprises 5-aminolevulinic acid (ALA) or a derivative thereof, or a salt of ALA or the derivative and an iron compound as active ingredients. Preferable examples of the ALAs can include ALA and various esters such as methyl ester, ethyl ester, propyl ester, butyl ester, and pentyl ester of ALA, and their hydrochlorides, phosphates, and sulfates. Preferable examples of the iron compound can include sodium ferrous citrate.
摘要翻译：本发明提供了一种用于促进移植物存活的药剂，其可以抑制不使用现有的免疫抑制剂的排斥反应，能够保持从供体排出的器官的新鲜度的器官保存溶液等。制备促进移植物存活的药物或器官保存溶液，其包含5-氨基乙酰丙酸（ALA）或其衍生物，或ALA或其衍生物和铁化合物的盐作为活性成分。 ALA的优选实例可以包括ALA和各种酯，例如ALA的甲酯，乙酯，丙酯，丁酯和戊酯，以及它们的盐酸盐，磷酸盐和硫酸盐。铁化合物的优选实例可包括柠檬酸亚铁钠。

4. 发明授权

US09314443B2 Enhancer of survival of transplanted organ 有权
标题翻译：移植器官生存增强
公开(公告)号：US09314443B2
公开(公告)日：2016-04-19
申请号：US14350488
申请日：2012-09-12
申请人： Ko Rii , Kiwamu Takahashi , Naomi Haga , Fuminori Abe , Tohru Tanaka , Motowo Nakajima , Hidenori Ito
发明人： Ko Rii , Kiwamu Takahashi , Naomi Haga , Fuminori Abe , Tohru Tanaka , Motowo Nakajima , Hidenori Ito
IPC分类号： A61K31/195 , A61K31/265 , A61K31/197 , A61K33/26 , A61K31/22 , A61K31/295 , A61K45/06
CPC分类号： A61K31/197 , A01N1/0226 , A61K31/22 , A61K31/295 , A61K33/26 , A61K35/17 , A61K45/06 , A61K2035/122 , A61K2035/124 , A61K2300/00
摘要： The present invention provides an agent for promoting graft survival which can suppress rejection without use of existing immunosuppressants, an organ preservation solution capable of maintaining the freshness of an organ excised from a donor, and the like. An agent for promoting graft survival or an organ preservation solution is prepared, which comprises 5-aminolevulinic acid (ALA) or a derivative thereof, or a salt of ALA or the derivative and an iron compound as active ingredients. Preferable examples of the ALAs can include ALA and various esters such as methyl ester, ethyl ester, propyl ester, butyl ester, and pentyl ester of ALA, and their hydrochlorides, phosphates, and sulfates. Preferable examples of the iron compound can include sodium ferrous citrate.
摘要翻译：本发明提供了一种用于促进移植物存活的药剂，其可以抑制不使用现有的免疫抑制剂的排斥反应，能够保持从供体排出的器官的新鲜度的器官保存溶液等。制备促进移植物存活的药剂或器官保存溶液，其包含5-氨基乙酰丙酸（ALA）或其衍生物，或ALA或其衍生物和铁化合物的盐作为活性成分。 ALA的优选实例可以包括ALA和各种酯，例如ALA的甲酯，乙酯，丙酯，丁酯和戊酯，以及它们的盐酸盐，磷酸盐和硫酸盐。铁化合物的优选实例可包括柠檬酸亚铁钠。

5. 发明申请

US20130158293A1 CANCER HEAT THERAPY-ENHANCING AGENT 有权
标题翻译：癌症治疗增强剂
公开(公告)号：US20130158293A1
公开(公告)日：2013-06-20
申请号：US13820303
申请日：2011-09-12
申请人： Taku Chibazakura , Tohru Tanaka , Kiwamu Takahashi , Motowo Nakajima , Fuminori Abe
发明人： Taku Chibazakura , Tohru Tanaka , Kiwamu Takahashi , Motowo Nakajima , Fuminori Abe
IPC分类号： C07C229/22
CPC分类号： C07C229/22 , A61K31/197
摘要： Provided is an enhancer for cancer thermotherapy not combined with photodynamic therapy. Cancer treatment not combined with photodynamic therapy is made available by using, as an enhancer for cancer thermotherapy, 5-aminolevulinic acids represented by formula (1): R2R1NCH2COCH2CH2COR3 (1) [wherein R1 and R2 each independently represent a hydrogen atom, an alkyl group, an acyl group, an alkoxycarbonyl group, an aryl group, or an aralkyl group; and R3 represents a hydroxy group, an alkoxy group, an acyloxy group, an alkoxycarbonyloxy group, an aryloxy group, an aralkyloxy group, or an amino group] or a salt thereof.
摘要翻译：提供了不与光动力疗法结合的癌症热疗的增强剂。通过使用作为癌症热疗的增强剂，可以通过使用由式（1）表示的5-氨基乙酰丙酸获得癌症治疗：R2R1NCH2COCH2CH2COR3（1）[其中R1和R2各自独立地表示氢原子，烷基，酰基，烷氧基羰基，芳基或芳烷基; R3表示羟基，烷氧基，酰氧基，烷氧基羰基氧基，芳氧基，芳烷氧基或氨基）或其盐。

6. 发明授权

US09474770B2 Prophylactic agent and/or therapeutic agent for sepsis 有权
标题翻译：脓毒症的预防剂和/或治疗剂
公开(公告)号：US09474770B2
公开(公告)日：2016-10-25
申请号：US14237407
申请日：2012-08-10
申请人： Kosaku Kinoshita , Katsuhisa Tanjoh , Akihiro Noda , Atsushi Sakurai , Tohru Tanaka , Kiwamu Takahashi , Motowo Nakajima , Fuminori Abe
发明人： Kosaku Kinoshita , Katsuhisa Tanjoh , Akihiro Noda , Atsushi Sakurai , Tohru Tanaka , Kiwamu Takahashi , Motowo Nakajima , Fuminori Abe
IPC分类号： A61K33/26 , A61K31/197 , A61K31/28 , A61K31/295 , A61K45/06
CPC分类号： A61K33/26 , A61K31/197 , A61K31/28 , A61K31/295 , A61K45/06
摘要： The present invention provides a sepsis therapeutic drug useful for prophylaxis and treatment of sepsis. A prophylactic agent and/or a therapeutic agent for sepsis containing 5-aminolevulinic acid (5-ALA) or a derivative thereof or a pharmacologically acceptable salt of 5-ALA or the derivative as an active ingredient is prepared. The prophylactic agent and/or the therapeutic agent preferably contains a metal-containing compound such as ferrous sodium citrate in addition to the ALAs. Preferred examples of the ALAs include ALA; various esters of ALA such as methyl, ethyl, propyl, butyl, and pentyl esters; and hydrochlorides, phosphates, sulfates of ALA and the esters.
摘要翻译：本发明提供了可用于预防和治疗败血症的败血症治疗药物。制备含有5-氨基乙酰丙酸（5-ALA）或其衍生物或5-ALA或其衍生物作为活性成分的药理学上可接受的盐的败血症的预防剂和/或治疗剂。除ALA之外，预防剂和/或治疗剂优选含有含金属的化合物如柠檬酸亚铁。 ALA的优选实例包括ALA; 各种ALA的酯如甲基，乙基，丙基，丁基和戊酯; 和盐酸盐，磷酸盐，ALA的硫酸盐和酯。

7. 发明授权

US09012502B2 Cancer heat therapy-enhancing agent 有权
标题翻译：癌症热疗增强剂
公开(公告)号：US09012502B2
公开(公告)日：2015-04-21
申请号：US13820303
申请日：2011-09-12
申请人： Taku Chibazakura , Tohru Tanaka , Kiwamu Takahashi , Motowo Nakajima , Fuminori Abe
发明人： Taku Chibazakura , Tohru Tanaka , Kiwamu Takahashi , Motowo Nakajima , Fuminori Abe
IPC分类号： A61K31/221 , C07C229/22 , A61K31/197
CPC分类号： C07C229/22 , A61K31/197
摘要： Provided is an enhancer for cancer thermotherapy not combined with photodynamic therapy. Cancer treatment not combined with photodynamic therapy is made available by using, as an enhancer for cancer thermotherapy, 5-aminolevulinic acids represented by formula (1): R2R1NCH2COCH2CH2COR3 (1) [wherein R1 and R2 each independently represent a hydrogen atom, an alkyl group, an acyl group, an alkoxycarbonyl group, an aryl group, or an aralkyl group; and R3 represents a hydroxy group, an alkoxy group, an acyloxy group, an alkoxycarbonyloxy group, an aryloxy group, an aralkyloxy group, or an amino group] or a salt thereof.
摘要翻译：提供了不与光动力疗法结合的癌症热疗的增强剂。通过使用作为癌症热疗的增强剂，可以通过使用由式（1）表示的5-氨基乙酰丙酸获得癌症治疗：R2R1NCH2COCH2CH2COR3（1）[其中R1和R2各自独立地表示氢原子，烷基，酰基，烷氧基羰基，芳基或芳烷基; R3表示羟基，烷氧基，酰氧基，烷氧基羰基氧基，芳氧基，芳烷氧基或氨基）或其盐。

8. 发明申请

US20140186464A1 PROPHYLACTIC AGENT AND/OR THERAPEUTIC AGENT FOR SEPSIS 有权
标题翻译：预防剂和/或治疗剂
公开(公告)号：US20140186464A1
公开(公告)日：2014-07-03
申请号：US14237407
申请日：2012-08-10
申请人： Kosaku Kinoshita , Katsuhisa Tanjoh , Akihiro Noda , Atsushi Sakurai , Tohru Tanaka , Kiwamu Takahashi , Motowo Nakajima , Fuminori Abe
发明人： Kosaku Kinoshita , Katsuhisa Tanjoh , Akihiro Noda , Atsushi Sakurai , Tohru Tanaka , Kiwamu Takahashi , Motowo Nakajima , Fuminori Abe
IPC分类号： A61K33/26 , A61K45/06 , A61K31/197
CPC分类号： A61K33/26 , A61K31/197 , A61K31/28 , A61K31/295 , A61K45/06
摘要： The present invention provides a sepsis therapeutic drug useful for prophylaxis and treatment of sepsis. A prophylactic agent and/or a therapeutic agent for sepsis containing 5-aminolevulinic acid (5-ALA) or a derivative thereof or a pharmacologically acceptable salt of 5-ALA or the derivative as an active ingredient is prepared. The prophylactic agent and/or the therapeutic agent preferably contains a metal-containing compound such as ferrous sodium citrate in addition to the ALAs. Preferred examples of the ALAs include ALA; various esters of ALA such as methyl, ethyl, propyl, butyl, and pentyl esters; and hydrochlorides, phosphates, sulfates of ALA and the esters.
摘要翻译：本发明提供了可用于预防和治疗败血症的败血症治疗药物。制备含有5-氨基乙酰丙酸（5-ALA）或其衍生物或5-ALA或其衍生物作为活性成分的药理学上可接受的盐的败血症的预防剂和/或治疗剂。除ALA之外，预防剂和/或治疗剂优选含有含金属的化合物如柠檬酸亚铁。 ALA的优选实例包括ALA; 各种ALA的酯如甲基，乙基，丙基，丁基和戊酯; 和盐酸盐，磷酸盐，ALA的硫酸盐和酯。

9. 发明授权

US4611135A Analog switch circuit and signal attenuator employing an analog switch circuit 失效
标题翻译：采用模拟开关电路的模拟开关电路和信号衰减器
公开(公告)号：US4611135A
公开(公告)日：1986-09-09
申请号：US531178
申请日：1983-09-09
申请人： Yoshio Nakayama , Fuminori Abe , Naofumi Nagasawa
发明人： Yoshio Nakayama , Fuminori Abe , Naofumi Nagasawa
IPC分类号： H03G3/02 , H03K17/16 , H03K17/687
CPC分类号： H03K17/164
摘要： An analog switch circuit comprises a first transfer gate (20) and a second transfer gate (23). The first transfer gate comprise first P-type and N-type field-effect transistors (21) and (22) having first electrodes thereof commonly connected through an output terminal (5) to a load (6) and second electrodes thereof commonly connected through an input terminal (4) to an input signal source (7) of an impedance lower than that of the load. The second transfer gate comprises second P-type and N-type field-effect transistors (24) and (25) of a gate size smaller than that of the respective transistors constituting the first transfer gate having the first and second electrodes connected in parallel with the first and second electrodes of the first P-type and N-type transistors, respectively. The second transfer gate is first turned on and then the first transfer gate is turned on, whereby a switching noise on the occasion of turning on of the first transfer gate is bypassed through the second transfer gate to the input signal source.
摘要翻译：模拟开关电路包括第一传输门（20）和第二传输门（23）。第一传输门包括第一P型和N型场效应晶体管（21）和（22），其第一电极通过输出端子（5）共同连接到负载（6），第二电极通过第二电极输入端子（4）输入到低于负载的阻抗的输入信号源（7）。第二传输门包括第二P型和N型场效应晶体管（24）和（25），其栅极尺寸小于构成第一传输门的各个晶体管的栅极尺寸，其具有与第一和第二电极并联连接的第一和第二电极第一P型和N型晶体管的第一和第二电极。第二传输门首先导通，然后第一传输门被导通，由此在第一传输门的导通时，开关噪声通过第二传输门被旁路到输入信号源。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式